Sanofi (India)

Recent papers from Sanofi (India)

1. Sample Size Reduction by Applying ML Based Causal Inference MethodsPharmaceutical Statistics · 2026
2. Mortality associated with facioscapulohumeral muscular dystrophy: A systematic literature reviewJournal of the Neurological Sciences · 2026
3. Comparison of Analysis and Design of Regular and Irregular Configuration of Multi Story Building in Various Seismic Zones2026
4. Comparison of Analysis and Design of Regular and Irregular Configuration of Multi Story Building in Various Seismic Zones- A Review2026
5. A Retrospective Chart Review Study on the Burden of Illness of Acid Sphingomyelinase Deficiency in BrazilJournal of Clinical Medicine · 2026
6. Real-World Effectiveness of Insulin Glargine 300 U/ml in People with Type 2 Diabetes Previously Treated with Tirzepatide: The DELIVER-T StudyDiabetes Therapy · 2025
7. Efficacy of Switching Therapy From Alglucosidase Alfa to Avalglucosidase Alfa on Respiratory Function in Participants With Late‐Onset Pompe Disease: A Post Hoc Analysis From the COMET Trial2025
8. The revised JBI critical appraisal tool for the assessment of risk of bias for analytical cross-sectional studiesJBI Evidence Synthesis · 2025
9. Multicenter, Phase 4 Clinical Study from India to Evaluate the Safety and Efficacy of Insulin Glargine 300 U/ml in Insulin-Naïve People with Type 2 Diabetes Uncontrolled on Oral Anti-hyperglycemic Drugs: SAFEGUARD StudyDiabetes Therapy · 2025
10. Declaration of Helsinki 2024: Too much too late?Perspectives in Clinical Research · 2024
11. Cost-effectiveness of caplacizumab in immune thrombotic thrombocytopenic purpura in the United StatesJournal of Managed Care & Specialty Pharmacy · 2024
12. Clinical trials of topical agents: Easy application but difficult designPerspectives in Clinical Research · 2024
13. Considerations for practical use of tree-based scan statistics for signal detection using electronic healthcare data: a case study with insulin glargineExpert Opinion on Drug Safety · 2024
14. The revised JBI critical appraisal tool for the assessment of risk of bias for cohort studiesJBI Evidence Synthesis · 2024
15. 618 - A Bayesian network meta-analysis comparing the efficacy of dupilumab versus tralokinumab in adults with severe atopic dermatitis with inadequate response or intolerance to cyclosporin ABritish Journal of Dermatology · 2024
16. Ab1276 Efficacy and Safety of Corticosteroid-Sparing Treatments in Patients With Polymyalgia Rheumatica: A Systematic Literature ReviewAnnals of the Rheumatic Diseases · 2024
17. Enhanced passive safety surveillance of high-dose and standard-dose quadrivalent inactivated split-virion influenza vaccines in Germany and Finland during the 2022/23 influenza seasonHuman Vaccines & Immunotherapeutics · 2024
18. The revised JBI critical appraisal tool for the assessment of risk of bias for quasi-experimental studiesJBI Evidence Synthesis · 2024
19. The role of remote data capture, wearables, and digital biomarkers in decentralized clinical trialsPerspectives in Clinical Research · 2023
20. Antibody Persistence Following Administration of a Hexavalent DTwP-IPV-HB-PRP~T Vaccine Versus Separate DTwP-HB-PRP~T and IPV Vaccines and Safety and Immunogenicity of a Booster Dose of DTwP-IPV-HB-PRP~T Administered With an MMR Vaccine in Healthy Infants in IndiaThe Pediatric Infectious Disease Journal · 2023